WP
KROS icon

Woodline Partners’s Keros Therapeutics KROS Stock Holding History

Woodline Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,875
Closed -$366K – 994
2025
Q1 		$366K Sell
35,875
-351,826
-91% -$4.09M ﹤0.01% 847
2024
Q4 		$6.14M Sell
387,701
-375,847
-49% -$19.5M 0.04% 443
2024
Q3 		$44.3M Sell
763,548
-12,297
-2% -$607K 0.37% 76
2024
Q2 		$35.5M Buy
775,845
+14,145
+2% +$760K 0.34% 85
2024
Q1 		$50.4M Buy
761,700
+177,908
+30% +$10.5M 0.46% 57
2023
Q4 		$23.2M Sell
583,792
-134,631
-19% -$4.22M 0.25% 122
2023
Q3 		$22.9M Buy
718,423
+438,722
+157% +$16.4M 0.27% 110
2023
Q2 		$11.2M Buy
279,701
+81,562
+41% +$3.58M 0.13% 192
2023
Q1 		$8.46M Buy
198,139
+1,440
+0.7% +$72.7K 0.12% 217
2022
Q4 		$9.45M Sell
196,699
-145,794
-43% -$6.81M 0.13% 223
2022
Q3 		$12.9M Buy
+342,493
New +$11.9M 0.18% 164
2022
Q2 		– Sell
-257,200
Closed -$14M – 843
2022
Q1 		$14M Buy
257,200
+180,988
+237% +$9.29M 0.23% 133
2021
Q4 		$4.46M Sell
76,212
-111,623
-59% -$5.57M 0.06% 298
2021
Q3 		$7.43M Buy
+187,835
New +$6.68M 0.12% 204

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Woodline Partners's KROS Position: Q2 2025 in Review

Woodline Partners sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 35,875 shares — an estimated $366K sold.

Woodline Partners first reported a position in KROS in Q3 2021 and held it in 14 quarters. The position peaked at $50.4M in Q1 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Woodline Partners reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 35,875 Keros Therapeutics shares in Q2 2025, an estimated $366K.
  • Woodline Partners first reported a position in Keros Therapeutics in Q3 2021 and held it in 14 quarters.
  • Woodline Partners's Keros Therapeutics position peaked at $50.4M in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.